Gofen & Glossberg LLC IL reduced its position in Shire PLC (NASDAQ:SHPG) by 1.4% during the third quarter, Holdings Channel reports. The fund owned 1,885 shares of the biopharmaceutical company’s stock after selling 26 shares during the period. Gofen & Glossberg LLC IL’s holdings in Shire PLC were worth $365,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. AMP Capital Investors Ltd boosted its position in shares of Shire PLC by 482.4% in the first quarter. AMP Capital Investors Ltd now owns 18,638 shares of the biopharmaceutical company’s stock worth $3,140,000 after buying an additional 15,438 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Shire PLC by 3,094.6% in the second quarter. BNP Paribas Arbitrage SA now owns 2,971 shares of the biopharmaceutical company’s stock worth $547,000 after buying an additional 2,878 shares during the last quarter. Fulton Bank N.A. boosted its position in shares of Shire PLC by 9.4% in the second quarter. Fulton Bank N.A. now owns 2,492 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 214 shares during the last quarter. Park National Corp OH acquired a new position in shares of Shire PLC during the second quarter worth approximately $257,000. Finally, Cacti Asset Management LLC acquired a new position in shares of Shire PLC during the second quarter worth approximately $177,000. Institutional investors own 24.49% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded up 0.7764% during midday trading on Friday, hitting $175.2300. The company’s stock had a trading volume of 908,697 shares. Shire PLC has a 12-month low of $147.60 and a 12-month high of $215.05.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.04. The company earned $3.45 billion during the quarter, compared to analyst estimates of $3.57 billion. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. During the same quarter last year, the firm earned $3.24 EPS. The business’s revenue was up 108.6% on a year-over-year basis. Equities analysts expect that Shire PLC will post $12.93 EPS for the current year.
A number of analysts recently commented on SHPG shares. Citigroup Inc. reissued a “buy” rating on shares of Shire PLC in a research report on Thursday, November 3rd. HSBC lowered Shire PLC from a “buy” rating to a “hold” rating in a research report on Monday, September 26th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a report on Monday, October 3rd. Zacks Investment Research upgraded Shire PLC from a “hold” rating to a “buy” rating and set a $211.00 price target for the company in a report on Friday, October 21st. Finally, Piper Jaffray Cos. set a $201.00 price target on Shire PLC and gave the company a “hold” rating in a report on Saturday, October 1st. Four analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $222.06.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.